TP53 and KMT2D mutations associated with worse prognosis in peripheral T‐cell lymphomas
Cancer Medicine · 2024
DOI: 10.1002/cam4.70027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Lingling Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Lymphoma, T-Cell, Peripheral, Tumor Suppressor Protein p53, Mutation, DNA-Binding Proteins. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
There are limited studies on mutation profiling for Peripheral T‐cell lymphomas (PTCL) in the Chinese population. We retrospectively analyzed the clinical and genetic landscape of 66 newly diagnosed Chinese patients. Targeted next‐generation sequencing (NGS) was performed for tissues from these patients. At least one mutation was detected in 60 (90.9%) patients, with a median number of 3 (0–7) mutations, and 32 (48.5%) cases detected with more than 4 mutations. The genes with higher mutation frequencies were TET2, RHOA, DNMT3A, IDH2, TP53, STAT3, and KMT2D respectively. When mutant genes are classified by functional group, the most prevalent mutations are related to epigenetics and signal transduction. IPI ≥2, PIT ≥2, and failure to achieve partial remission (PR) were factors for inferior progression‐free survival (PFS) and overall survival (OS). Multivariate analysis showed TP53 was an adverse factor for PFS (HR, 3.523; 95% CI, 1.262–9.835; p = 0.016), and KMT2D was an adverse factor for OS (HR, 10.097; 95% CI, 1.000–101.953; p = 0.048). Mutation profiling could help differentiate distinct types of PTCL and serve as a useful tool for determining treatment options and prognoses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
- Department of Hematology, The First People's Hospital of Yancheng, The Yancheng Clinical College of Xuzhou Medical University, Yancheng, China.
- Department of Hematology, The Affiliated People's Hospital of Jiangsu University, Zhenjiang, China.
ORCID-Profile: Jing Chen, Yuexin Cheng, Jingsong He, Zhen Cai, Yi Zhao
Förderung
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Wang, L., Yang, L., Guan, F., Chen, J., Cheng, Y., Miao, Y., He, J., Cai, Z., Huang, H., & Zhao, Y. (2024). TP53 and KMT2D mutations associated with worse prognosis in peripheral T‐cell lymphomas. Cancer Medicine. https://doi.org/10.1002/cam4.70027
Vancouver
Wang L, Yang L, Guan F, Chen J, Cheng Y, Miao Y, et al. TP53 and KMT2D mutations associated with worse prognosis in peripheral T‐cell lymphomas. Cancer Medicine. 2024. doi:10.1002/cam4.70027
BibTeX
@article{Wang2024,
author = {Wang, Lingling and Yang, Lei and Guan, Fangshu and Chen, Jing and Cheng, Yuexin and Miao, Yuqing and He, Jingsong and Cai, Zhen and Huang, He and Zhao, Yi},
title = {TP53 and KMT2D mutations associated with worse prognosis in peripheral T‐cell lymphomas},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70027}
}
EUVIMED